Teleflex Subsidiary Gets CE Mark for Catheter Device

Shortly after agreeing to sell its orthopedics business, other divisions of Teleflex continue to make gains. The company’s Semprus BioSciences subsidiary has been issued CE certification from its notified body, the DEKRA Certification Group of the Netherlands, to market the company’s Nylus peripherally inserted central catheter (PICC) with Semprus Sustain technology in the European Union.

The Nylus PICC uses a long-lasting polymer designed to reduce the attachment of platelets and blood proteins at the surface of the medical device. According to Teleflex, the device has been shown to reduce platelet adhesion and thrombus accumulation through in vitro and animal testing.

“This clearance enables us to further advance a new standard of care in PICC catheters,” said David L. Lucchino, vice president of Semprus Technology, and of strategic and business development of Teleflex. “Our novel technology, with its ability to work in blood products and long-term duration, holds great potential to reduce infection and thrombus-related complications for patients—while substantially decreasing associated healthcare costs.”

Based in Limerick, Pa., Teleflex produces products for the critical care market. Its subsidiary, Semprus BioSciences, is headquartered in Cambridge, Mass., and was acquired by Teleflex in May.